New drug combo shows promise for Hard-to-Treat leukemia
NCT ID NCT02997761
First seen Apr 24, 2026 · Last updated May 18, 2026 · Updated 5 times
Summary
This study tested a combination of two drugs, ibrutinib and blinatumomab, in 19 adults with B-cell acute lymphoblastic leukemia that had returned or stopped responding to treatment. The goal was to see how well the drugs worked together to stop cancer growth. The study is complete, and results focus on remission rates and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.